ArticleInternational journal of nanomedicine2014
In vivo enhancement of anticancer therapy using bare or chemotherapeutic drug-bearing nanodiamond particles.
Article in International journal of nanomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 61 citations in OpenAlex.
- Nanodiamonds as Possible Tools for Improved Management of Bladder Cancer and Bacterial Cystitis.International journal of molecular sciences · 2022Review
- Application of Carbon Nanoparticles in Oncology and Regenerative Medicine.International journal of molecular sciences · 2021Review
- Pharmacodynamic Studies of Fluorescent Diamond Carriers of Doxorubicin in Liver Cancer Cells and Colorectal Cancer Organoids.Nanotechnology, science and applications · 2021Article
- Functionalization of Polyethyleneimine with Hollow Cyclotriveratrylene and Its Subsequent Supramolecular Interaction with Doxorubicin.Molecules (Basel, Switzerland) · 2020Article
- Targeting Nanodiamonds to the Nucleus in Yeast Cells.Nanomaterials (Basel, Switzerland) · 2020Article
- Nanodiamonds with powerful ability for drug delivery and biomedical applications: Recent updates on in vivo study and patents.Journal of pharmaceutical analysis · 2020Review
- Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer.International journal of molecular sciences · 2018Review
- rLj-RGD3 Suppresses the Growth of HeyA8 Cells in Nude Mice.Molecules (Basel, Switzerland) · 2017Article
- New Methods of Esterification of Nanodiamonds in Fighting Breast Cancer-A Density Functional Theory Approach.Molecules (Basel, Switzerland) · 2017Article
- Nanodiamonds for Medical Applications: Interaction with Blood in Vitro and in Vivo.International journal of molecular sciences · 2016Article
- Brazilian red propolis: phytochemical screening, antioxidant activity and effect against cancer cells.BMC complementary and alternative medicine · 2015Article
- Solid-phase synthesis, characterization, and cellular activities of collagen-model nanodiamond-peptide conjugates.Biopolymers · 2015Article
- Analysis of the cytotoxicity of carbon-based nanoparticles, diamond and graphite, in human glioblastoma and hepatoma cell lines.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated the use of nanodiamond particles (NDs) as a promising material for drug delivery in vivo and in vitro.
methodsHepG2 cells (a human hepatic carcinoma cell line) were used to determine the characteristics of a nanodiamond-doxorubicin complex (ND-DOX) when taken up by cells in vitro using laser scanning confocal microscopy and dialysis experiments. We also compared the survival rate and histopathology of tumor-bearing mice after treatment with NDs or ND-DOX in vivo.
resultsIn vitro investigation showed that ND-DOX has slow and sustained drug release characteristics compared with free doxorubicin. In vivo, the survival rate of tumor-bearing mice treated with ND-DOX was four times greater than that of mice treated with free doxorubicin. Interestingly, the survival rate in mice treated with NDs alone was close to that of mice treated with free doxorubicin. This indicates that treatment with ND-DOX can prolong the lifespan of tumor-bearing mice significantly compared with conventional doxorubicin and that NDs can have this effect as well. Histopathological analysis showed that neither the NDs nor ND-DOX were toxic to the kidney, liver, or spleen in contrast with the well-known toxic effects of free doxorubicin on the kidney and liver. Further, both the bare NDs and ND-DOX could suppress tumor growth effectively.
conclusionNDs can potentially prolong survival, and ND-DOX may act as a nanodrug with promising chemotherapeutic efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.